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Background/aim: There are various instruments to assess quality of life (QoL) in patients with atrial fibrillation (AF). The aim of this
study is to determine the reliability and validity of the Turkish version of the University of Toronto Atrial Fibrillation Severity Scale
(AFSS).
Materials and methods: The AFSS and Short Form-36 (SF-36) were completed by 130 patients with documented AF. The Canadian
Cardiovascular Society Severity in Atrial Fibrillation (SAF) scale and European Heart Rhythm Association (EHRA) scale were also
utilized by the attending physicians. To assess test–retest reliability, the AFSS was readministered to 47 clinically stable patients at a
1-month follow-up visit. Internal consistency reliability, test–retest reproducibility, and construct validity were evaluated.
Results: The mean age of the patients was 63.1 ± 10.9 years and 58.5% of patients were male. The outcome scores of the Turkish version
of the AFSS showed good correlations with theoretically related SF-36 domains. Additionally, AFSS outcome scores showed a linear
correlation with the SAF and EHRA scores. Cronbach’s alpha values for internal consistency were consistent and similar with the
English language version of the AFSS. Intraclass correlation coefficients for reproducibility exceeded 0.80 for every item.
Conclusion: Convergent–divergent and known-groups validity and reliability were established for the Turkish version of the University
of Toronto AFSS.
Key words: Atrial fibrillation, health-related quality of life, validation, disease-specific questionnaire

1. Introduction
Atrial fibrillation is the most common chronic arrhythmia,
affecting 1%–2% of the general population (1). Healthrelated quality of life (HRQoL) is significantly impaired
in patients with AF when compared with healthy controls
(2). Rate versus rhythm control trials have demonstrated
that both of the treatment strategies have a similar effect
on mortality and morbidity in patients with AF (3–5).
Therefore, controlling the symptoms of AF and improving
HRQoL are important determinants in making decisions
for the appropriate treatment strategy.
Quality of life (QoL) is a subjective phenomenon;
however, standardized questionnaires have been developed
for accurate quantification of the perceived QoL (2). Two
main types of questionnaires have been defined: a) generic,
which are used to evaluate HRQoL in different populations,
and b) disease-specific, which are used to evaluate patients
with specific conditions and focus on items or symptoms
related to the condition under study (6).
* Correspondence: nkahya77@yahoo.com
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The University of Toronto Atrial Fibrillation Severity
Scale (AFSS) is a disease-specific HRQoL questionnaire
designed for patients with AF (7–9). It consists of 19 items
combined into 3 parts to capture total AF burden, health
care utilization, and the severity of AF-related symptoms.
The AFSS was tested according to the standardized
psychometric parameters of content validity, reliability,
and variability (7,8).
The aim of this study was to determine the reliability
and validity of the Turkish version of the University of
Toronto AFSS in patients with AF.
2. Materials and methods
Patients with AF attending a cardiology outpatient clinic
were invited to participate in the study; 130 patients who
were willing to provide informed consent were recruited.
Patients with AF of any classification were eligible for
enrollment as long as their AF was documented by
electrocardiogram (ECG) or Holter monitoring. We
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excluded patients who were unwilling to participate in the
study or were illiterate and unable to self-administer the
questionnaires. Data on sociodemographic characteristics
(age, sex, educational level, and working status), as well
as clinical data including AF classification (paroxysmal,
persistent, or permanent), treatment strategy (rate vs.
rhythm control), current medications, underlying heart
diseases, and other comorbidities were recorded. Twelvelead ECGs and transthoracic echocardiography were
performed.
The attending physicians provided a Severity in Atrial
Fibrillation (SAF) classification and European Heart
Rhythm Association (EHRA) classification for every
patient. Subsequently, all patients completed the Short
Form-36 (SF-36) generic HRQoL instrument and the
disease-specific AFSS. The study protocol was approved by
the local ethics committee.
2.1. Outcome measures
The Canadian Cardiovascular Society Severity in Atrial
Fibrillation (SAF) is a scale utilized by physicians to assess
the functional consequences of symptoms and to quantify
the effect of AF on a patient’s quality of life (10). SAF class
ratings range from 0 (asymptomatic) to 4 (severe impact of
symptoms on HRQoL and activities of daily living).
The EHRA classification is score for AF symptoms
(11). It provides a simple quantification of symptoms that
are attributable to functional consequences of AF. The 4
EHRA classes are defined from I (no symptoms) to IV
(disabling symptoms).
The SF-36 is a widely used generic HRQoL scale with
36 items combined into 8 domains to measure physical
functioning, role functioning, social functioning, mental
health, vitality, pain, and general health perceptions (12).
The Turkish version of the SF-36 has been previously
validated (13).
The University of Toronto AFSS is a disease-specific
QoL questionnaire. It is composed of 3 parts, A, B, and
C. Part A includes questions regarding overall wellbeing (scored on a Likert scale from 0 to 10) and the
frequency, duration, and overall severity of AF episodes.
Part B includes questions regarding the presence and the
frequency of the cardioversions, specialist appointments,
emergency room visits, and hospitalizations within the past
year, and part C is composed of questions regarding the
presence and severity of individual symptoms attributable
to AF (such as palpitations, dyspnea, dizziness, weakness,
or chest pain). A measure of total AF burden is obtained
by combining the measures of frequency, duration, and
overall severity of AF episodes. Each of the 3 measures
contributes equally, and each measure ranges from 1 to 10
to yield total AF burden scores ranging from 3–30. Higher
scores indicate greater AF burden. Symptom severity
is measured by summing the values of the questions in

part C to yield a total score ranging from 0 to 35. Higher
scores indicate more severe symptoms (7,9,14). The AFSS
was professionally translated into Turkish with backtranslations into English for verification for this study.
Accepted translation strategies were used (15,16).
2.2. Validity and reliability
Convergent–divergent and known-groups validities were
examined to establish the construct validity. Convergent
validity establishes the correlation between 2 measures of
different constructs that are theoretically related to each
other. Divergent validity was used to demonstrate the
poor correlation of theoretically unrelated constructs. For
convergent and divergent validity, the SF-36 domains were
correlated with AFSS outcome scores. Additionally, AFSS
outcome scores were tested for differences among SAF and
EHRA classes and were correlated with them for knowngroups validity.
The reliability was assessed in terms of internal
consistency, which measures the extent to which the items
in the same construct are interrelated and test–retest
reproducibility. Test–retest reproducibility was evaluated
in clinically stable AF patients whose therapy was not
changed. Clinically stable patients completed the AFSS
at baseline and at a 1-month follow-up visit. Test–retest
reliability was measured using these scores.
2.3. Statistical analysis
Patient sociodemographic and clinical characteristics were
described as frequencies, means ± standard deviations,
or median (minimum–maximum). Scores from each
domain of the SF-36 and AFSS were reported as median
(minimum–maximum). The correlations between AFSS
outcome scores and the other outcome measures (SF36, EHRA, and SAF classes) were determined by using
Spearman correlations to test convergent, divergent, and
known-group validity. An r value of >0.60 was considered
to indicate a strong correlation, whereas r values between
0.35 and 0.60 indicated a moderate correlation. If the r
value was <0.35, the correlation was considered to be weak
(17,18).
The internal consistency of the questionnaire was
measured by Cronbach’s alpha and test–retest reliability
was measured using intraclass correlation coefficient.
The relationship between the AFSS outcome scores
and the other variables (sociodemographic and clinical
characteristics) was compared with the Mann–Whitney U
test or the Kruskal–Wallis test.
3. Results
The mean age of the study group was 63.1 ± 10.9 years, and
58.5% of the patients (n = 76) were male. Sociodemographic
and clinical characteristics of the patients are presented in
Table 1. Paroxysmal AF was present in 30% of patients, and
16.2% (n = 22) were on antiarrhythmic drugs to maintain
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Table 1. Sociodemographic and clinical characteristics of the
patients (n = 130).
Age, years

64 (32–84)

Male

76 (58.5%)

Family status
Single
Married
Widow

4 (3.1%)
106 (81.5%)
20 (15.4%)

Education
Primary school
Secondary school
High school
University

72 (55.4%)
16 (12.3%)
20 (15.4%)
22 (16.9%)

Employment
Housewife
Working

42 (32.3%)
18 (13.8%)

Retired
Unemployed

65 (50%)
5 (3.8%)

AF pattern
Paroxysmal
Persistent
Permanent

39 (30%)
8 (6.2%)
83 (63.8%)

Left ventricle EF (%)

60 (22–70)

Left atrial dimension (mm)

45 (30–76)

Underlying heart disease
Hypertension
Valvular
Coronary artery disease
Cardiomyopathy
Congenital heart disease
Pacemaker

73 (56.2%)
37 (28.5%)
24 (18.5%)
16 (12.3%)
3 (2.3%)
9 (6.9%)

Diabetes mellitus

28 (21.5%)

Prior embolic event

17 (13.1%)

Prior cardioversion

26 (20%)

Prior ablation

0 (0%)

Drugs
Amiodarone
Propafenone
Beta blocker
Verapamil
Diltiazem
Digoxin
Warfarin
Acetylsalicylic acid
Clopidogrel
Other medication

11 (8.5%)
10 (7.7%)
75 (57.7%)
10 (7.7%)
16 (12.3%)
23 (17.7%)
90 (69.2%)
29 (22.3%)
10 (7.7%)
98 (75.4%)

Data are presented as median (minimum–maximum). EF =
ejection fraction.
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sinus rhythm. Sixty-nine percent of the patients were on
oral anticoagulation therapy (Table 1).
All patients completed AFSS in <5 min. Missing
response rate was 2.3% for item 4 (global well-being),
7% for items 5 (AF frequency) and 6 (AF duration), and
3% for item 8 (perceived severity of the first AF episode).
Response rate was 100% for all other items.
The relation between AFSS outcome scores and
demographic and clinical variables was investigated.
AFSS outcome scores (global well-being, total AF burden,
symptom severity) were not related to sociodemographic
and clinical variables (sex, family status, educational level,
employment, AF pattern, comorbidities), except for age
and presence of coronary artery disease. Older patients
reported lower AF burdens (frequency, duration, and
AF severity) than younger patients (r = –0.2; P = 0.04).
Patients with coronary artery disease reported higher AF
burdens compared to patients without coronary artery
disease (17.0 ± 7.4 vs. 13.3 ± 6.7; P = 0.02).
The correlation between SF-36 domain scores and
AFSS outcome scores is shown in Table 2. The global
well-being subscale in the AFSS was correlated with all
domains of the SF-36, but the correlation was stronger with
the general health domain. There was a weak–moderate
correlation between total AF burden and domains of the
SF-36. On the other hand, symptom severity correlated at
a moderate–high level with all domains of the SF-36 but
had the strongest correlation with physical function and
limitations in physical functioning.
AFSS outcome scores for every EHRA and SAF class
are shown in Tables 3 and 4. The EHRA and SAF are
similar scales, both of which quantify symptoms and
their impact on patient’s daily living and functionality.
As expected, we observed a strong positive correlation
between the SAF and EHRA classes rated by the physicians
(r = 0.89, P < 0.001). AF frequency, duration, severity, and
symptom severity scores increased in accordance with the
increases in SAF and EHRA classes (Tables 3 and 4). Total
AF burden and symptom severity were strongly correlated
with the patient’s SAF or EHRA class. There was a negative
linear relationship between the global well-being subscale
and EHRA and SAF classes. The number of emergency
room visits and hospitalizations within the last year,
which are theoretically related to disease burden, were also
correlated with EHRA and SAF classes.
This scale has internal consistency (Cronbach α) of 0.88
for symptom severity, α = 0.75 for AF severity, α = 0.70 for
AF burden, and α = 0.62 for health care utilization. The
intraclass correlation coefficients were higher than 0.80 for
every item, demonstrating a good test–retest reliability.
4. Discussion
Previous trials have failed to demonstrate the mortality
benefit of a specific therapy in patients with AF, with the
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Table 2. Correlation between AFSS scores and SF-36 scores.

Global well being
AF frequency†
AF duration†
AF severity†
Total AF burden
Symptoms

Physical
Social
Role physical Bodily pain General health Vitality
functioning
functioning

Role emotional

Mental
health

0.41**
–0.42**
–0.39**
–0.36**
–0.50**
–0.72**

0.33**
–0.31**
–0.23**
–0.35**
–0.32**
–0.53**

0.44**
–0.33**
–0.25**
–0.35**
–0.34**
–0.55**

0.38**
–0.47**
–0.36**
–0.41**
–0.51**
–0.69**

0.24**
–0.19*
–0.19*
–0.28**
–0.26**
–0.58**

0.49**
–0.26**
–0.17
–0.19*
–0.25**
–0.52**

0.45**
–0.39**
–0.26**
–0.34**
–0.39**
–0.66**

0.37**
–0.35**
–0.32**
–0.36**
–0.42**
–0.56**

*Correlation is significant at 0.05 level. **Correlation is significant at 0.01 level. The increasing scores for each AFSS subscale indicate
increasing symptoms and severity except for global well-being, where higher scores indicate better well-being. For SF-36 domains,
higher scores indicate better perceived health.
†AF frequency, AF duration, and AF severity are components of total AF burden.
Table 3. AFSS outcome scores by EHRA classification and the correlation between the AFSS outcome scores and EHRA classification.

Global well-being (1–10)*
AF frequency (1–10)*
AF duration (1–10)*
AF severity (1–10)*
Total AF burden (3–30)*
Symptoms (0–35)*
Health care utilization
Cardioversion (0–7)*
Emergency room visit (0–7)*
Hospitalization (0–7)*
Specialist visit (0–7)*

EHRA 1
(n = 32)

EHRA 2
(n = 53)

EHRA 3
(n = 31)

EHRA 4
(n = 14)

P-value

Correlation
coefficient (P-value)

8 (5–10)
1 (1–5)
1 (1–7.5)
1.2 (1–10)
3 (2–17.5)
2 (0–17)

7 (2–10)
4 (1–10)
2.5 (1–10)
6 (1–10)
14.2 (2–28.5)
10 (0–21)

5 (3–10)
7 (1–10)
6.2 (1.2–10)
7 (1–10)
17.9 (9.2–27)
16 (3–31)

6 (3–10)
7 (2–10)
6.2 (3.2–10)
8.7 (4.5–10)
21.9 (16.7–30)
24.5 (6–34)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

–0.37 (<0.001)
0.57 (<0.001)
0.62 (<0.001)
0.57 (<0.001)
0.70 (<0.001)
0.74 (<0.001)

0 (0–3)
0 (0–1)
0 (0–1)
1 (0–5)

0 (0–4)
0 (0–5)
0 (0–3)
2 (0–7)

0 (0–5)
1 (0–6)
1 (0–5)
3 (0–7)

0 (0–7)
3 (0–7)
1 (0–5)
3 (0–7)

0.09
<0.001
<0.001
0.001

0.15 (0.09)
0.50 (<0.001)
0.37 (<0.001)
0.34 (<0.001)

Data are presented as median (minimum–maximum). *The numbers indicate the range of scores.
Increasing scores indicate increasing symptoms and severity, except for global well-being, where increasing scores indicate better
perceived well-being.

exception of anticoagulation therapy (1). On the other
hand, patients with AF have an impaired QoL that is
comparable to postmyocardial infarction patients (8).
Therefore, symptom reduction and improvement of the
patient’s well-being have become important objectives in
the management of AF (1). A patient’s well-being is usually
expressed as QoL, which is a subjective phenomenon and
usually does not correlate with the objective measures of
disease severity (8). The most common approach to assess
HRQoL is to apply standardized questionnaires. The
University of Toronto AFSS has been validated to assess
the impact of AF on quality of life (7) and has been used in
clinical research (8,9,14,19). In this study, we have shown
the validity and reliability of the Turkish version of the
AFSS.
In our study, the first objective was the translation of the
AFSS questionnaire, on which a consensus was obtained.
The Turkish version of the AFSS was well perceived by

Turkish patients with no need for any changes. Although the
educational level of our study population was relatively low,
response rates were acceptable. The response rate in part B
and part C was 100%, while the response rate was 97.7% for
item 4 (global well-being), 93% for items 5 (AF frequency)
and 6 (AF duration), and 97% for item 8 (perceived severity
of the first AF episode). The patients who did not respond to
items 5 and 6 had permanent AF. These patients had been
previously informed about their rhythm problem but had
never been symptomatic due to AF. The patients who did not
respond to item 8 reported that they could not remember
the severity of the first AF episode.
Construct validity was obtained by correlating the AFSS
outcome scores with the SF-36 and physician-estimated SAF
and EHRA classes. The global well-being subscale showed
consistency with the general health domain of the SF-36.
The SF-36 has performed reasonably well in AF in previous
studies, with the largest changes seen in scales related to
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Table 4. AFSS scores by SAF classification and the correlation between AFSS outcome scores and SAF classification.

Global WB¶
AF frequency¶
AF duration¶
AF severity¶
Total AF burden†
Symptoms‡
Health care utilization
CardioversionϮ
Emergency room visitϮ
HospitalizationϮ
Specialist visitϮ

SAF 0 (n = 17)

SAF 1 (n = 34)

SAF 2 (n = 28)

SAF 3 (n = 28)

SAF 4 (n = 23)

Correlation
coefficient

8 (5–10)
1 (1–5)
1 (1–6)
1 (1–10)
3 (3–17.2)
2 (0–11)

7 (2–10)
2 (1–9)
1.2 (1–7.5)
5 (1–9)
9.9 (3–18.2)
4 (0–18)

7.5 (3–10)
5 (1–10)
2.5 (1.2–10)
6.2 (2–10)
14.9 (4.2–28.5)
11 (3–20)

5 (3–10)
7 (1–10)
6.2 (1.2–10)
7 (1–9.5)
18.3 (9.2–25.7)
14.5 (3–27)

6 (3–10)
7 (1–10)
6.2 (1.2–10)
8.5 (4.5–10)
21.9 (9.2–30)
24 (6–34)

–0.30**
0.61**
0.65**
0.53**
0.74**
0.74**

0 (0–3)
0 (0–1)
0 (0–1)
1 (0–5)

0 (0–2)
0 (0–5)
0 (0–3)
1 (0–6)

0 (0–2)
0 (0–5)
0 (0–2)
2.5 (0–7)

0 (0–5)
1 (0–6)
0 (0–5)
3 (0–7)

0 (0–7)
3 (0–7)
1 (0–5)
3 (0–7)

0.10
0.45**
0.26*
0.30**

Data are presented as median (minimum–maximum).
*Correlation is significant at 0.05 level. **Correlation is significant at 0.01 level.
¶The score of the items ranges from 0 to 10.
†The score ranges from 3 to 30. ‡The score of the symptom severity subscale ranges from 0 to 35.
Ϯ
The score of the items in the health care utilization subscale ranges from 0 to 7.
Increasing scores indicate increasing symptoms and severity, except for global well-being, where increasing scores indicate better
perceived well-being.

physical function (5). In accordance with this, we found a
strong correlation between symptom severity and the SF36 domains related to physical function. However, there
was weak–moderate correlation between AF frequency, AF
duration, and AF severity and SF-36 domains. This finding is
also in line with previous studies (9). Dorian et al. reported
that there is a subjective distinction between the AF burden
of the AFSS and estimates of general quality of life measures
(9).
Known-groups validity was demonstrated by relating the
AFSS outcome scores with the EHRA and SAF classes. We
observed a positive linear correlation with AFSS subscales
(AF frequency, duration, severity, and symptom severity) and
EHRA and SAF classes, whereas a negative correlation was
found between global well-being and EHRA and SAF classes.
EHRA and SAF classifications were strongly correlated
with the total AF burden and symptom severity. Similarly,
Dorian et al. demonstrated a positive linear correlation
with symptom severity and SAF classification (10). The SAF
scale evaluates data about severity, as well as frequency of
subjective symptoms related to AF, to determine the impact
of AF on patient’s well-being (20). Therefore, it is not an
unexpected result that patient-perceived AF frequency and
duration are in relation with SAF classification. However,
Dorian et al. found no linear relationship between SAF score
and AF duration or frequency (10). The discordance of the
results between the 2 studies might be related to dissimilar
patient characteristics. Since AF patients may present a wide
variety of symptoms occurring in a wide range of frequency
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and duration (21), different patient populations may be
responsible for the disparity regarding the relation of AF
frequency or duration and SAF classification.
Cronbach alpha values in our study are consistent and
similar to those of the English version of the AFSS (7).
Older age was related with a lesser AF burden in our
study, which is in accordance with previous studies. Older
patients are often less symptomatic than younger patients
(22). Howes et al. showed that elderly patients with chronic
AF have similar QoL and exercise capacity compared with
age-matched controls in sinus rhythm (23). In our study, the
presence of coronary artery disease was related with a higher
AF burden. Previous studies found that the New York Heart
Association (NYHA) functional class was an independent
predictor for worse QoL in patients with AF (9,22). In this
study we did not evaluate the NYHA classes of the patients,
but left ventricular systolic dysfunction was significantly
more prevalent in patients with coronary artery disease.
Accordingly, the higher AF burden observed in patients with
coronary artery disease might be related to lower ejection
fraction and lower functional capacity.
The results of our study indicate that Turkish version of
the AFSS is a reliable and valid instrument to assess impact
of AF on patients’ QoL.
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